Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609323 · ClinicalTrials.gov registry record · Phase 2
Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)
A Phase 2 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00609323 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 23 participants.
The verdict
NCT00609323, a Phase 2 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Pliaglis™ (lidocaine and tetracaine) Cream 7%/7% is a topical local anesthetic cream that forms a pliable peel on the skin when exposed to air. When applied to intact skin, Pliaglis provides local dermal analgesia by the release of lidocaine and tetracaine from the peel into the skin. Pliaglis is currently approved in the United States for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, and facial laser resurfacing. This study will evaluate lidocaine and tetracaine cream 7%/7% for the treatment of pain associated with postherpetic neuralgia (PHN).
Interventions
- DRUG Placebo
- DRUG lidocaine and tetracaine cream 7%/7%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609323
The ClinicalTrials.gov registry entry for NCT00609323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00609323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609323 about?
NCT00609323 is a clinical study titled "Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)". Pliaglis™ (lidocaine and tetracaine) Cream 7%/7% is a topical local anesthetic cream that forms a pliable peel on the skin when exposed to air. When applied to intact skin, Pliaglis provides local dermal analgesia by the release of lidocaine and tetracaine from the peel into the skin. Pliaglis is c...
What is the current status of trial NCT00609323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00609323?
The interventions under investigation include: Placebo (DRUG), lidocaine and tetracaine cream 7%/7% (DRUG).
Who is sponsoring clinical trial NCT00609323?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.